Lee W-Y
Department of Pathology, Chi Mei Medical Center and Department of Pathology, National Cheng Kung University Hospital, Tainan, Taiwan.
Cytopathology. 2005 Oct;16(5):227-32. doi: 10.1111/j.1365-2303.2005.00259.x.
Telomerase is active in almost all cancers from various organs but is not detectable in most normal cells. Thus, telomerase activity might be a universal and specific marker for diagnosing malignancy. The aim was to evaluate the potential use of the ELISA-based TRAP assay to detect malignancy in pleural effusion, and to compare it with conventional cytological examination.
Using the ELISA-based TRAP assay, telomerase activity was examined in 94 consecutive pleural effusions submitted for cytological examination.
According to the results of cytology, the 94 samples were divided into two groups: group I, 79 non-malignant pleural effusions, including group IA, no association with a malignant tumour, a control group (n = 63), and group IB, associated with a malignant tumour (n = 16); and group II, 15 malignant pleural effusions. Telomerase activity was detected in five of 63 samples in group IA (7.9%), four of 16 samples in group IB (25%), and six of 15 samples in group II (40%). All five false-positive effusions were from patients with tuberculosis. Comparing group II with group IA, the TRAP assay showed 40% sensitivity, 92.1% specificity, 54.5% positive and 86.6% negative predictive value, and 82.1% accuracy. However, the detection rate of the TRAP assay (88.9%) was higher than that of the cytological examination (66.7%) in lung cancer-inflicted pleural effusions.
The ELISA-based TRAP assay is relatively insensitive; therefore, it is unsuitable as a routine diagnostic tool for pleural effusion. False-positive telomerase activity due to lymphocytic contamination may weaken its diagnostic value for malignant effusions in a tuberculosis-endemic area.
端粒酶在几乎所有来自各种器官的癌症中都有活性,但在大多数正常细胞中无法检测到。因此,端粒酶活性可能是诊断恶性肿瘤的一种通用且特异的标志物。本研究旨在评估基于酶联免疫吸附测定(ELISA)的端粒酶重复扩增法(TRAP)检测胸腔积液中恶性肿瘤的潜在用途,并将其与传统细胞学检查进行比较。
使用基于ELISA的TRAP法,对94例连续送检细胞学检查的胸腔积液进行端粒酶活性检测。
根据细胞学结果,94个样本分为两组:第一组,79例非恶性胸腔积液,包括IA组,与恶性肿瘤无关,为对照组(n = 63),以及IB组,与恶性肿瘤有关(n = 16);第二组,15例恶性胸腔积液。在IA组的63个样本中有5个检测到端粒酶活性(7.9%),IB组的16个样本中有4个(25%),第二组的15个样本中有6个(40%)。所有5例假阳性积液均来自结核病患者。将第二组与IA组比较,TRAP法显示敏感性为40%,特异性为92.1%,阳性预测值为54.5%,阴性预测值为86.6%,准确性为82.1%。然而,在肺癌所致胸腔积液中,TRAP法的检测率(88.9%)高于细胞学检查(66.7%)。
基于ELISA的TRAP法相对不敏感;因此,它不适合作为胸腔积液的常规诊断工具。淋巴细胞污染导致的端粒酶活性假阳性可能会削弱其在结核病流行地区对恶性积液的诊断价值。